secwatch.observer — SEC 8-K summary
======================================

Issuer:     RVL Pharmaceuticals plc (—)
CIK:        0001739426
Form:       8-K
Filed at:   2023-11-27T23:59:59+00:00
Accession:  0001104659-23-121234
Event type: other_material
Sentiment:  negative
Materiality: 0.95
Item codes: 1.03, 2.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

RVL subsidiaries exit Chapter 11; parent to wind down with no recovery for equity holders
--------------------------------------------------------------------------------

- On Nov 22, 2023, Athyrium Capital Management exchanged debt for 97.5% equity in NewCo, which holds 100% of RVL Pharmaceuticals, Inc.
- Holders of SPA Rejection Unsecured Claims received pro rata share of remaining 2.5% equity in NewCo.
- RVL plc retained substantially no assets post-plan; intends to petition Irish High Court to wind up by end of 2024.
- No recovery for holders of RVL plc's 111,406,043 ordinary shares; all shares have no residual value.
- Bankruptcy Court confirmed Amended Prepackaged Plan on Nov 20, 2023, effective Nov 22, 2023.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1739426/000110465923121234/0001104659-23-121234-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1739426/000110465923121234/tm2331439d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-23-121234

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer